FTC files administrative complaint against the three largest PBMs
Federal Trade Commission
- Named role
- Respondent
- HHI coverage
- 0 paired / 1
Exact official-record label
OptumRx, Inc.
Pharmacy benefit manager named in FTC study and administrative complaint records.
Exact source label, not a standalone legal-entity, ownership, liability, or market-power determination.
Official labelOptumRx, Inc.
Policy organizationOptumRx, Inc.Official label / 2 records / 2024
- Record identityExact source labelNot legal-entity resolution
- Official coverage2 dated records2024
- Market scope1 contextLinked by the official record
- Permitted useRecord tracingNot a liability finding
Official record chronology
Why this exact label appears
Sep 20, 2024
LitigationDocket Docket No. 9437
Federal Trade Commission
FTC files administrative complaint against the three largest PBMs
The FTC brought an administrative action alleging anticompetitive and unfair rebating and formulary practices involving Caremark, Express Scripts, OptumRx, and affiliated GPOs.
Named as Respondent
The FTC administrative complaint names OptumRx as a respondent.
Jul 9, 2024
MonitoringFederal Trade Commission
FTC releases interim staff report on prescription drug middlemen
The FTC published interim findings on PBM concentration and vertical integration, including aggregate shares for the largest PBMs.
Named as Report subject
The FTC interim report identifies OptumRx among the six PBMs that received Section 6(b) orders.
Descriptive economic context
Public HHI evidence around each record
Each row searches the linked market profile for strict pre-event, same-year, and strict post-event observations. Missing anchors remain visible.
0Paired
0One-sided
2Unavailable
- Strict pre
- Unavailable
- No earlier HHI
- Event year
- Unavailable
- No same-year HHI
- Strict post
- Unavailable
- No later HHI
- Pre-post change
- Not available
- Pair not available
- Strict pre
- Unavailable
- No earlier HHI
- Event year
- Unavailable
- No same-year HHI
- Strict post
- Unavailable
- No later HHI
- Pre-post change
- Not available
- Pair not available
Before/after HHI differences are descriptive comparisons between discrete public releases. They do not estimate the causal effect of the policy event.
Bounded market context
Markets linked by the cited records
United States / Health care
PBMs
2 named records / 0 paired HHI windows
RespondentReport subject
A market link records the scope named by the official event. It does not establish that every named organization participates throughout that market or define a relevant antitrust market for a different matter.
Source custody
Official records behind the dossier
Federal Trade Commission / agency report
FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices
Accessed Jul 17, 2026. Federal Trade Commission, FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices, September 20 2024.
Federal Trade Commission / agency report
Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies
Accessed May 16, 2026. Federal Trade Commission, FTC Releases Interim Staff Report on Prescription Drug Middlemen, July 9 2024.
Reproducible record packet
Reuse the exact organization dossier
Filtered index and relationship routes preserve the organization slug, exact role, event ID, market context, source URL, and inference guardrails.
- Organization ID
- pent-optumrx
- Profile slug
- optumrx-inc
- Named edges
- 2
- License
- CC BY 4.0
Official-record interpretation boundary
These dossiers compile exact organization labels from official public records. They do not resolve corporate identity, ownership, control, affiliate status, liability, or market power beyond what the cited record expressly states.
A relationship means an official source names the organization in connection with the dated record. It does not by itself establish liability, market power, ownership, control, or that the organization participates in every market linked to that record.